| Literature DB >> 28356149 |
Ling Na1, Joel E Streim2, Liliana E Pezzin3,4, Jibby E Kurichi1, Dawei Xie1, Hillary R Bogner1, Pui L Kwong1, Steven M Asch5, Sean Hennessy6,7.
Abstract
BACKGROUND: Although health disparities have been documented between Medicare beneficiaries based on age (<65 years vs. older age groups), underuse of recommended medical care in younger beneficiaries has not been thoroughly investigated. In this study, we aim to identify and characterize vulnerabilities of the younger Medicare age group (aged <65 years) in relation to older age groups (aged 65-74 years and ≥75 years) and to explore age group as a determinant of use of recommended care among Medicare beneficiaries.Entities:
Keywords: Health disparity; Medicare; Quality of care; Recommended care; Younger beneficiaries
Mesh:
Year: 2017 PMID: 28356149 PMCID: PMC5371256 DOI: 10.1186/s12913-017-2168-5
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Sociodemographic, functional and clinical characteristics of medicare beneficiaries (2001–2008) by age group
| Variable | Total | Age < 65 | Age 65–74 | Age ≥ 75 |
|
|---|---|---|---|---|---|
| Gender | <.0001 | ||||
| Male | 13,649 (45.2) | 2853 (52.6) | 5360 (46.3) | 5436 (40.3) | |
| Female | 16,468 (54.8) | 2348 (47.4) | 5929 (53.7) | 8191 (59.7) | |
| Race/Ethnicity | <.0001 | ||||
| Non-Hispanic White | 23,893 (79.2) | 3459 (67.3) | 9017 (79.9) | 11,417 (83.7) | |
| Non-Hispanic Black | 2966 (9.7) | 1007 (18.6) | 1007 (8.7) | 952 (7.0) | |
| Hispanic | 2372 (7.9) | 580 (11.2) | 913 (8.0) | 879 (6.3) | |
| Other | 886 (3.2) | 155 (2.9) | 352 (3.4) | 379 (2.9) | |
| Living arrangement | <.0001 | ||||
| Retirement community | 1905 (5.6) | 101 (2.2) | 430 (3.6) | 1374 (9.7) | |
| With spouse | 14,124 (51.2) | 1649 (39.1) | 7004 (62.6) | 5471 (41.6) | |
| With children | 3158 (9.5) | 658 (11.4) | 802 (7.0) | 1698 (12.1) | |
| With others | 2762 (7.8) | 1597 (23.6) | 589 (5.2) | 576 (4.2) | |
| Alone | 8168 (25.9) | 1196 (23.8) | 2464 (21.6) | 4508 (32.5) | |
| Dual enrollment in Medicare and Medicaid | <.0001 | ||||
| No | 24,292 (83.5) | 2409 (56.4) | 9984 (89.4) | 11,899 (87.8) | |
| Yes | 5825 (16.5) | 2792 (43.6) | 1305 (10.6) | 1728 (12.2) | |
| Education | <.0001 | ||||
| High school diploma or above | 21,252 (72.8) | 3527 (69.1) | 8543 (77.4) | 9182 (68.5) | |
| No high school diploma | 8865 (27.2) | 1674 (30.9) | 2746 (22.6) | 4445 (31.5) | |
| Living in metropolitan area | <.0001 | ||||
| No | 7942 (25.0) | 1598 (29.0) | 3092 (25.1) | 3252 (23.1) | |
| Yes | 22,175 (75.0) | 3603 (71.0) | 8197 (74.9) | 10,375 (76.9) | |
| Proxy report | <.0001 | ||||
| No | 27,492 (92.8) | 4277 (87.2) | 10,757 (95.4) | 12,458 (91.9) | |
| Yes | 2625 (7.2) | 924 (12.8) | 532 (4.6) | 1169 (8.1) | |
| Vision impairment | <.0001 | ||||
| No | 27,674 (92.7) | 4621 (87.9) | 10,752 (95.8) | 12,301 (90.8) | |
| Yes | 2443 (7.3) | 580 (12.1) | 537 (4.2) | 1326 (9.2) | |
| Hearing impairment | <.0001 | ||||
| No | 27,934 (93.5) | 4890 (93.8) | 10,745 (95.5) | 12,299 (90.8) | |
| Yes | 2183 (6.5) | 311 (6.2) | 544 (4.5) | 1328 (9.2) | |
| Cognitive, developmental and psychiatric disordersa | <.0001 | ||||
| No | 25,662 (87.3) | 2766 (60.9) | 10,442 (93.0) | 12,454 (91.8) | |
| Yes | 4455 (12.7) | 2435 (39.1) | 847 (7.0) | 1173 (8.2) | |
| Average number of comorbiditiesb | 2.2 ± 0 | 2.3 ± 0 | 2.1 ± 0 | 2.4 ± 0 | <.0001 |
| Activity of Daily Living (ADL) Stages | <.0001 | ||||
| 0 | 19,874 (68.3) | 2599 (45.4) | 8846 (79.9) | 8429 (63.5) | |
| I | 5181 (16.5) | 1156 (25.2) | 1398 (11.8) | 2627 (18.9) | |
| II | 2622 (7.9) | 656 (13.7) | 568 (4.5) | 1398 (9.6) | |
| III | 2047 (6.2) | 656 (13.5) | 417 (3.3) | 974 (6.7) | |
| IV | 393 (1.1) | 134 (2.3) | 60 (0.5) | 199 (1.3) | |
| Instrumental Activity of Daily Living (IADL) stages | <.0001 | ||||
| 0 | 16,911 (59.4) | 1339 (23.8) | 8169 (74.0) | 7403 (56.2) | |
| I | 5332 (17.6) | 1063 (24.9) | 1670 (14.2) | 2599 (18.8) | |
| II | 2979 (9.5) | 1046 (22.2) | 675 (5.6) | 1258 (8.9) | |
| III | 4089 (11.4) | 1500 (25.0) | 665 (5.3) | 1924 (13.2) | |
| IV | 806 (2.1) | 253 (4.0) | 110 (0.8) | 443 (2.9) | |
aCognitive, developmental, and psychiatric disorders include: mental retardation, Alzheimer’s/dementia and mental/psychiatric disorder
bNumber of comorbidities including: hypertension, myocardial infarction, angina/chronic heart disease, other heart disease, stroke, diabetes mellitus, Parkinson’s disease, emphysema/asthma/chronic obstructive pulmonary disease, rheumatoid arthritis, non-rheumatoid arthritis, osteoporosis/soft bones and other (non-skin) cancer
Receipt of recommended care among medicare beneficiaries (2001–2008) by age group at the indicator level
| Overall | Age < 65 | Age 65–74 | Age ≥75 | |
|---|---|---|---|---|
| Total number of opportunities for recommended care (unweighted denominator) | 89,076 | 14,015 | 32,372 | 42,689 |
| Total number of instances of recommended care received (unweighted numerator) | 64,157 | 8702 | 23,582 | 31,873 |
| Weighted percent of recommended care received | 72.1% | 63.9% | 72.7% | 74.8% |
Receipt of recommended care by indicator among medicare beneficiaries (2001–2008) by age group
| Recommended care indicator | Overall | Age < 65 | Age 65–74 | Age ≥ 75 |
| |
|---|---|---|---|---|---|---|
| Raw numerator/denominator | Weighted percent (%) | Weighted percent (%) | Weighted percent (%) | Weighted percent (%) | ||
| Acute Myocardial Infarction (AMI) | ||||||
| Visit within 4 weeks following discharge of patients hospitalized for acute myocardial infarction | 231/298 | 79 | 84 | 79 | 78 | 0.748 |
| Cholesterol test every 6 months for patients hospitalized for myocardial infarction who have hypercholesterolemia | 224/365 | 64 | 71 | 69 | 58 | 0.188 |
| Anemia | ||||||
| Gastrointestinal workup for patients with iron deficiency anemia no later than 3 months after iron deficiency | 355/1112 | 33 | 34 | 37 | 30 | 0.273 |
| Hematocrit/hemoglobin between 1 and 6 months following initial diagnosis of anemia | 1723/2576 | 68 | 67 | 67 | 69 | 0.633 |
| Angina | ||||||
| Visit within 4 weeks following discharge of patients hospitalized for unstable angina | 193/234 | 83 | 76 | 83 | 86 | 0.407 |
| Visit every 6 months for patients with chronic stable angina | 1826/1940 | 94 | 92 | 93 | 96 | 0.135 |
| Follow-up visit or hospitalization within 4 weeks of initial diagnosis of unstable angina | 196/236 | 84 | 77 | 82 | 89 | 0.150 |
| Lipid profile within 6 months after initial diagnosis of angina | 59/767 | 9 | X | 14 | 4 | 0.0003 |
| Breast Cancer | ||||||
| Interval from biopsy and definitive therapy less than 3 months for patients with breast cancer and eventual mastectomy | 60/79 | 73 | X | 70 | 81 | 0.273 |
| Mammogram within 3 months preceding an initial diagnosis of breast cancer | 110/182 | 61 | X | 60 | 63 | 0.917 |
| Chest x-ray within 3 months preceding or following initial diagnosis of breast cancer | 96/182 | 51 | 43 | 54 | 51 | 0.631 |
| Visit within 12 months for breast cancer patients who have undergone mastectomy without cytotoxic chemotherapy | 71/71 | 100 | X | 100 | 100 | N/A |
| Mammography every year for patients with a history of breast cancer | 416/629 | 69 | 70 | 78 | 61 | 0.0004 |
| Cerebrovascular Accident (CVA) | ||||||
| Carotid imaging within 2 weeks of initial diagnosis for patients hospitalized for carotid artery stroke | 235/312 | 75 | 95 | 68 | 75 | <.0001 |
| Interval between carotid imaging and carotid endarterectomy less than 2 months for cerebrovascular accident patients with eventual carotid endarterectomy | 112/134 | 84 | X | 87 | 83 | 0.501 |
| Visit within 4 weeks following discharge of patients for cerebrovascular accident | 379/571 | 67 | 57 | 75 | 64 | 0.011 |
| Transient Ischemic Attack (TIA) | ||||||
| Electrocardiogram within 2 days of initial diagnosis of transient ischemic attack | 92/621 | 15 | X | 16 | 14 | 0.748 |
| Interval between carotid imaging and carotid endarterectomy less than 2 months for TIA patients with eventual carotid endarterectomy | 45/54 | 85 | X | 91 | 82 | 0.012 |
| Visit within 4 weeks following discharge of patients hospitalized for transient ischemic attack | 184/237 | 79 | 61 | 95 | 74 | <.0001 |
| Visit every year for patients with diagnosis of transient ischemic attack | 1540/1596 | 97 | 96 | 97 | 96 | 0.740 |
| Cholelithiasis | ||||||
| Cholecystectomy within 1 month preceding or 3 months following diagnosis of cholelithiasis and one or more of the following: cholecystitis, cholangitis, gallstone pancreatitis | 282/699 | 41 | 43 | 48 | 34 | 0.030 |
| Chronic Obstructive Pulmonary Disease (COPD) | ||||||
| Visit every 6 months for patients with chronic obstructive pulmonary disease | 4732/5197 | 91 | 90 | 91 | 92 | 0.236 |
| Congestive Heart Failure (CHF) | ||||||
| Chest x-ray within 3 months of initial diagnosis of congestive heart failure | 1097/1580 | 69 | 72 | 64 | 71 | 0.067 |
| Electrocardiogram within 3 months of initial diagnosis of congestive heart failure | 1023/1578 | 66 | 67 | 66 | 66 | 0.953 |
| Visit within 4 weeks following discharge of patients hospitalized for congestive heart failure | 490/663 | 74 | 71 | 82 | 70 | 0.032 |
| Visit every 6 months for patients with congestive heart failure | 4142/4527 | 92 | 91 | 93 | 91 | 0.201 |
| Depression | ||||||
| Visit within 2 weeks following discharge of patients hospitalized for depression | 95/173 | 53 | 49 | 55 | 57 | 0.593 |
| Diabetes Mellitus (DM) | ||||||
| Glycosylated hemoglobin every 6 months for patients with diabetes | 3499/6756 | 54 | 52 | 58 | 50 | <.0001 |
| Eye exam every year for patients with diabetes | 3160/6491 | 49 | 34 | 50 | 54 | <.0001 |
| Visit within 4 weeks following discharge of patients hospitalized for diabetes | 295/430 | 68 | 71 | 63 | 70 | 0.466 |
| Visit every 6 months for patients with diabetes | 6185/6756 | 92 | 89 | 92 | 92 | 0.036 |
| Gastrointestinal Bleeding | ||||||
| Visit within 4 weeks following discharge of patients hospitalized for gastrointestinal bleeding | 273/373 | 73 | 51 | 74 | 78 | 0.001 |
| Hematocrit within 4 weeks following discharge of patients hospitalized for gastrointestinal bleeding | 201/373 | 54 | 36 | 57 | 58 | 0.025 |
| Follow-up visit within 4 weeks of initial diagnosis of gastrointestinal bleeding | 491/676 | 74 | 74 | 77 | 69 | 0.195 |
| Hypertension | ||||||
| Visit within 4 weeks following discharge of patients hospitalized with malignant or otherwise severe hypertension | 49/74 | 63 | X | 62 | 76 | 0.0002 |
| Preventive Care | ||||||
| Visit every year | 17,905/19,535 | 92 | 87 | 91 | 94 | <.0001 |
| Assessment of visual impairment every 2 years | 9363/16,759 | 56 | 34 | 57 | 64 | <.0001 |
| Mammography every 2 years for females aged between 45 and 75 (inclusive) years | 2728/4240 | 65 | 58 | 67 | 61 | <.0001 |
Note. According to the Centers for Medicare and Medicaid Services, cell size below 11, marked with an X, is not permitted for publication
Fig. 1Disparities in receipt of recommended care among younger versus older age groups (<65, 65–74, ≥75)
Logistic Regression Models Predicting Receipt of Recommended Care among Medicare Beneficiaries (2001–2008)
| Variables | Model 1 | Model 2 with ADL stages | Model 2 with IADL stages | |||
|---|---|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| |
| Age (ref: 65–74) | <.0001 | <.0001 | <.0001 | |||
| <65 | 0.66 (0.62–0.71) | <.0001 | 0.75 (0.70–0.80) | <.0001 | 0.75 (0.69–0.80) | <.0001 |
| ≥75 | 1.11 (1.07–1.16) | <.0001 | 1.15 (1.10–1.20) | <.0001 | 1.15 (1.10–1.20) | <.0001 |
| Gender (ref: female) | ||||||
| Male | 0.86 (0.82–0.90) | <.0001 | 0.86 (0.82–0.90) | <.0001 | ||
| Race/Ethnicity (ref: Non-Hispanic White) | 0.005 | 0.005 | ||||
| Hispanic | 0.95 (0.87–1.05) | 0.337 | 0.95 (0.86–1.04) | 0.277 | ||
| Non-Hispanic Black | 0.88 (0.82–0.95) | 0.0004 | 0.88 (0.82–0.95) | 0.0005 | ||
| Other | 0.96 (0.86–1.08) | 0.527 | 0.96 (0.85–1.08) | 0.464 | ||
| Education (ref: high school diploma) | ||||||
| No high school diploma | 0.85 (0.81–0.89) | <.0001 | 0.85 (0.81–0.89) | <.0001 | ||
| Living Arrangement (ref: live with spouse) | <.0001 | <.0001 | ||||
| Alone | 0.88 (0.83–0.92) | <.0001 | 0.87 (0.83–0.92) | <.0001 | ||
| Retirement community | 0.95 (0.87–1.03) | 0.199 | 0.95 (0.87–1.03) | 0.188 | ||
| With children | 0.77 (0.72–0.83) | <.0001 | 0.77 (0.72–0.83) | <.0001 | ||
| With others | 0.82 (0.75–0.89) | <.0001 | 0.83 (0.76–0.90) | <.0001 | ||
| Residential Location (ref: Non-Metropolitan location) | ||||||
| Metropolitan location | 1.14 (1.09–1.18) | <.0001 | 1.13 (1.08–1.18) | <.0001 | ||
| Dual Enrollment in Medicare and Medicaid (ref: Medicare only) | ||||||
| Dual enrollment | 1.06 (1.00–1.13) | 0.056 | 1.06 (1.00–1.13) | 0.072 | ||
| Proxy Response (ref: no) | ||||||
| Proxy | 0.87 (0.81–0.93) | <.0001 | 0.90 (0.84–0.96) | 0.003 | ||
| Conditions (ref: no) | ||||||
| Vision impairment | 1.01 (0.94–1.09) | 0.731 | 1.02 (0.94–1.10) | 0.694 | ||
| Hearing impairment | 0.95 (0.88–1.02) | 0.162 | 0.96 (0.89–1.03) | 0.242 | ||
| Cognitive, developmental, and psychiatric disorders* | 0.89 (0.83–0.94) | <.0001 | 0.90 (0.84–0.96) | <.0001 | ||
| Sum of comorbidities** | 1.12 (1.11–1.14) | <.0001 | 1.12 (1.10–1.13) | 0.001 | ||
| Stage (ref: Stage 0) | <.0001 | <.0001 | ||||
| Stage I | 0.92 (0.88–0.97) | 0.003 | 0.99 (0.94–1.05) | 0.763 | ||
| Stage II | 0.87 (0.81–0.93) | <.0001 | 0.89 (0.84–0.96) | 0.001 | ||
| Stage III | 0.80 (0.74–0.87) | <.0001 | 0.87 (0.81–0.93) | <.0001 | ||
| Stage IV | 0.64 (0.54–0.76) | <.0001 | 0.69 (0.61–0.78) | <.0001 | ||
Note: Ref=reference category. For a variable that has more than two categories, a total p value of the variable is reported
Model 1 is adjusted only for age group; model 2’s are further adjusted for sociodemographics, health and clinical characteristics and ADL stages and IADL stages separately
* Cognitive, developmental, and psychiatric disorders include: mental retardation, Alzheimer's/dementia, and mental/psychiatric disorder
** Sum of comorbidities include: hypertension, myocardial infarction, angina/chronic heart disease, other heart disease, stroke, diabetes mellitus, Parkinson's disease, emphysema/asthma/chronic obstructive pulmonary disease, rheumatoid arthritis, non-rheumatoid arthritis, osteoporosis/soft bones, and other (non-skin) cancer